Experimental drug hopes to boost chemo against tough pancreatic cancer
NCT ID NCT03310632
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial investigates whether adding antroquinonol (Hocena) to standard chemotherapy (nab-paclitaxel and gemcitabine) can safely treat people with metastatic pancreatic cancer that has not yet been treated. The study has two phases: first, finding the best dose, and second, checking how well the combination works. Participants must have stage IV pancreatic cancer and have not received prior systemic therapy for metastatic disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Antroquinonol (Hocena)
What this could lead to
If successful, this could offer a new combination treatment option for people with advanced pancreatic cancer.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not confirm benefit. Side effects from the drug combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Galeterone + Gemcitabine for Pancreatic Cancer T NCT04098081
- EGFR BATs for Pancreatic Cancer Trial (NCT03269526)
- AB801 Trial for Bile Duct & Pancreatic Cancer NCT07619313
- GLP-1 Drug Semaglutide in GI Cancers Trial NCT07627191
- EUS-PEF Ablation for Pancreatic Tumors - NCT07619417
- Pancreatic Cancer Early Detection Study (NCT06122896)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 5505, South Korea
-
Cancer Treatment Centers of America - Eastern Regional Medical Center
Philadelphia, Pennsylvania, 19124, United States
-
Cancer Treatment Centers of America at Southeastern Regional Medical Center
Newnan, Georgia, 30265, United States
-
Florida Hospital Tampa
Tampa, Florida, 33613, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Inha University Hospital
Incheon, 22322, South Korea
-
Maryland Oncology Hematology
Rockville, Pennsylvania, 20850, United States
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
-
National Cheng Kung University Hospital
Tainan, Tainan, 704, Taiwan
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Taipei Veterans General Hospital
Taipei, Taipei, 11217, Taiwan